文献速递放疗物理与技术姑息放疗与转移瘤

近距离放疗联合免疫治疗的前景与挑战

Brachytherapy: Perspectives for combined treatments with immunotherapy.
PubMed 文献 · Clin Transl Radiat Oncol · 2025-01-19

本文综述近距离放疗(BT)联合免疫检查点抑制剂(ICI)的潜力:BT 可能更好保护淋巴引流区和肠道菌群,减少放疗免疫抑制效应,并因剂量不均匀性提供广泛剂量范围。临床数据稀少,仅有晚期癌症完全局部缓解和远隔效应的病例报告,需随机试验验证并优化临床前模型。

要点

  • BT 较其他放疗技术可能更好保护淋巴引流区和肠道菌群,减少免疫抑制。
  • BT 植入体积内固有剂量不均匀性提供广泛剂量范围,可能增加免疫浸润激活概率。
  • BT 联合 ICI 的临床数据稀少,仅有完全局部缓解和远隔效应的病例报告。

核心结论

  • BT 联合免疫治疗 particularly ICI 是有前景的策略,可增强局部控制并利用药物免疫调节与放疗的协同。
  • 临床前模型显示放疗可刺激免疫应答,但也对免疫效应物产生毒性,联合试验结果矛盾。
  • BT 联合 ICI 在晚期癌症的临床数据稀少,病例报告显示潜在获益,但需随机试验验证。

研究设计与样本

  • 综述类文章,讨论 BT 联合免疫治疗的 perspectives,包括临床前模型和临床数据。
  • 文中讨论随机临床试验的理想设计,但未报告具体检索范围或样本量。

主要发现

  • BT 较其他放疗技术可能更好保护淋巴引流区和肠道菌群,从而减少放疗的免疫抑制效应。
  • BT 因植入体积内固有剂量不均匀性提供广泛剂量范围,可能增加免疫浸润激活概率,尤其免疫激活最佳剂量尚未确立。
  • 临床前模型显示放疗可刺激免疫应答,也可对免疫效应物产生毒性,联合试验结果矛盾。
  • BT 联合 ICI 在晚期癌症的临床数据稀少,病例报告显示完全局部缓解和远隔效应。

关键数值与推荐

  • 免疫激活最佳剂量尚未 firmly established,原文未给出具体阈值或数值。

临床怎么用

  • BT 的剂量学特异性可能提供多种优势,应进一步探索。
  • 需优化放射模态以增强免疫增强效应。
  • 需优化临床前模型以更好分析 BT 涉及的特定生物学效应,结合免疫调节全身治疗。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Combining brachytherapy with immunotherapies, particularly immune checkpoint inhibitors (ICIs), is a promising approach for potentiating both local control of the tumor and fully exploiting the synergies between pharmaceutic immunomodulation and radiotherapy. Compared to other radiotherapy techniques, BT has a potential to better spare lymphatic drainage areas and gut microbiota, thus reducing the immunosuppressive effects of radiation therapy. In addition, it delivers a broad range of doses due to inherent dose inhomogeneity within the implanted volume. This variability increases the probability that immune infiltrates would be activated, particularly since the optimal dose for immune activation is not yet firmly established. Even if preclinical models show that radiotherapy can stimulate immune responses, it can also induce toxic effects on immune effectors and combination trials show conflicting outcomes. There is a need for refining radiation modalities to enhance immune potentiation. The dosimetric specificities of BT may offer various advantages and should be explored further. Scarce clinical data on combining brachytherapy with ICIs in advanced cancer suggest potential benefits, with case reports of complete local responses and abscopal effects. However, validation requires a large number of patients in randomized clinical trials for which ideal design is discussed. In parallel with ongoing clinical developments, there is a need to refine preclinical models in order to better analyze the specific biological effects involved in BT, in light of immunomodulatory systemic treatments.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Serre R, Gabro A, Andraud M, et al. Brachytherapy: Perspectives for combined treatments with immunotherapy. Clin Transl Radiat Oncol. 2025. PMID: 40226301. doi:10.1016/j.ctro.2025.100924

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。